文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

正确剂量,即刻执行:脓毒症或脓毒性休克危重患者床旁实时数据驱动个体化抗生素给药的两中心随机临床试验

Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial.
PubMed 文献 · Crit Care · 2022-09-05
一句话结论在脓毒症或脓毒性休克危重患者中,AutoKinetics个体化给药可行、安全,并显著提高环丙沙星的目标达成率(69% vs 3%,OR 62.5)。

这项两中心随机临床试验纳入252例确诊或疑似感染且乳酸>2 mmol/L或需血管升压药的成人脓毒症或脓毒性休克患者,随机接受AutoKinetics决策支持系统个体化给药或标准给药,涉及万古霉素、环丙沙星、美罗培南和头孢曲松四种抗生素。主要终点为随机化后24小时内的药代动力学目标达成率。因COVID-19疫情提前终止。环丙沙星干预组目标达成率为69%,对照组为3%(OR 62.5,CI 11.4-1173.78,p<0.001),且达标更快(26小时,CI 18-42小时,p<0.001)、更好(提高65%,CI 49-84%,p<0.001)。其他抗生素的AutoKinetics给药未改善目标达成率。临床终点无显著差异,更高剂量未导致死亡率或肾衰竭增加。作者认为个体化给药可行、安全,并显著改善环丙沙星的目标达成率。

要点

  • 环丙沙星干预组24小时内目标达成率69%,对照组3%(OR 62.5,CI 11.4-1173.78,p<0.001)。
  • 环丙沙星干预组达标更快(26小时,CI 18-42小时,p<0.001),达标率提高65%(CI 49-84%,p<0.001)。
  • 万古霉素、美罗培南和头孢曲松的AutoKinetics给药未改善目标达成率。
  • 死亡率、ICU住院时间和急性肾损伤发生率等临床终点无显著差异;更高剂量未增加死亡率或肾衰竭。
  • 研究纳入252例后因COVID-19疫情提前终止。

适用人群与场景

  • 成人确诊或疑似感染,且乳酸>2 mmol/L或需要血管升压药治疗的脓毒症或脓毒性休克危重患者。

诊断标准与关键阈值

  • 主要终点为随机化后24小时内的药代动力学目标达成率。

处置流程与药物剂量

  • 随机分配至AutoKinetics决策支持系统个体化给药组或标准给药组,涉及万古霉素、环丙沙星、美罗培南和头孢曲松四种抗生素。

研究设计与关键结果

  • 两中心随机临床试验,纳入252例脓毒症或脓毒性休克成人患者后因COVID-19疫情提前终止。
  • 环丙沙星干预组主要终点目标达成率69%,对照组3%(OR 62.5,CI 11.4-1173.78,p<0.001)。
  • 环丙沙星干预组达标更快(26小时,CI 18-42小时,p<0.001),达标率提高65%(CI 49-84%,p<0.001)。
  • 其他抗生素(万古霉素、美罗培南、头孢曲松)的AutoKinetics给药未改善目标达成率。
  • 死亡率、ICU住院时间和急性肾损伤发生率等临床终点无显著差异;更高剂量未导致死亡率或肾衰竭增加。

证据类型、等级与局限

  • 证据类型:两中心随机临床试验。
  • 局限:研究纳入252例后因COVID-19疫情提前终止。

对床旁实践的改变

  • 作者认为,在危重患者中个体化给药可行、安全,并显著改善环丙沙星的目标达成率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Adequate antibiotic dosing may improve outcomes in critically ill patients but is challenging due to altered and variable pharmacokinetics. To address this challenge, AutoKinetics was developed, a decision support system for bedside, real-time, data-driven and personalised antibiotic dosing. This study evaluates the feasibility, safety and efficacy of its clinical implementation.

METHODS: In this two-centre randomised clinical trial, critically ill patients with sepsis or septic shock were randomised to AutoKinetics dosing or standard dosing for four antibiotics: vancomycin, ciprofloxacin, meropenem, and ceftriaxone. Adult patients with a confirmed or suspected infection and either lactate > 2 mmol/L or vasopressor requirement were eligible for inclusion. The primary outcome was pharmacokinetic target attainment in the first 24 h after randomisation. Clinical endpoints included mortality, ICU length of stay and incidence of acute kidney injury.

RESULTS: After inclusion of 252 patients, the study was stopped early due to the COVID-19 pandemic. In the ciprofloxacin intervention group, the primary outcome was obtained in 69% compared to 3% in the control group (OR 62.5, CI 11.4-1173.78, p < 0.001). Furthermore, target attainment was faster (26 h, CI 18-42 h, p < 0.001) and better (65% increase, CI 49-84%, p < 0.001). For the other antibiotics, AutoKinetics dosing did not improve target attainment. Clinical endpoints were not significantly different. Importantly, higher dosing did not lead to increased mortality or renal failure.

CONCLUSIONS: In critically ill patients, personalised dosing was feasible, safe and significantly improved target attainment for ciprofloxacin.

TRIAL REGISTRATION: The trial was prospectively registered at Netherlands Trial Register (NTR), NL6501/NTR6689 on 25 August 2017 and at the European Clinical Trials Database (EudraCT), 2017-002478-37 on 6 November 2017.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Roggeveen LF, Guo T, Fleuren LM, et al. Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock-a two-centre randomised clinical trial. Crit Care. 2022. PMID: 36064438. doi:10.1186/s13054-022-04098-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。